GLUT5-KHK axis-mediated fructose metabolism drives proliferation and chemotherapy resistance of colorectal cancer.

Zhiyong Shen, Zhenkang Li, Yuechen Liu, Yongsheng Li, Xiaochuang Feng, Yizhi Zhan, Mingdao Lin, Chuanfa Fang, Yuan Fang, Haijun Deng

Cancer letters 2022 May 28

filter terms:

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Abundant metabolic fuels have been implicated as potential drivers of CRC. However, it remains unclear whether fructose, an ample sugar in daily diets, is essential for CRC growth. In the present study, we found that glucose levels were always insufficient in human CRC tissues. Compensating for this, fructose was flexibly utilized by tumor cells as an alternative energy source to maintain proliferation and exert chemotherapy resistance in vitro by upregulating GLUT5, a major fructose transporter encoded by SLC2A5. Mechanistically, in glucose-deprived but fructose-rich environments, GLUT5 could interact with ketohexokinase and inhibit its autophagy-dependent degradation, thus trapping fructose into glycolysis and tricarboxylic acid cycle for the malignant growth of CRC cells. In addition, reducing dietary fructose or pharmacological blockade of fructose utilization significantly reduced CRC growth and sensitized CRC cells to chemotherapy in vivo. Taken together, our findings highlight the role of elevated fructose utilization mediated by the GLUT5-KHK axis in governing CRC growth and imply that efforts to refine fructose intake or inhibit fructose-mediated actions may serve as potential therapeutic strategies. Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Citation

Zhiyong Shen, Zhenkang Li, Yuechen Liu, Yongsheng Li, Xiaochuang Feng, Yizhi Zhan, Mingdao Lin, Chuanfa Fang, Yuan Fang, Haijun Deng. GLUT5-KHK axis-mediated fructose metabolism drives proliferation and chemotherapy resistance of colorectal cancer. Cancer letters. 2022 May 28;534:215617